Treatment cost development of patients undergoing remission induction chemotherapy: A pharmacoeconomic analysis before and after introduction of posaconazole prophylaxis

Mycoses

Volumn 57, Issue 2, 2014, Pages 90-97

  Heimann, Sebastian M ^a   Cornely, Oliver A ^a,b,c   Vehreschild, Maria J G T ^a,c   Glossmann, Jan ^a   Kochanek, Matthias ^a   Kreuzer, Karl Anton ^a   Hallek, Michael ^a   Vehreschild, Jörg J ^a,c  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Cost effectiveness; Costs; Neutropenia; Pharmacoeconomic analysis; Posaconazole; Prophylaxis

Indexed keywords

ANTIINFECTIVE AGENT; CYTARABINE; DAUNORUBICIN; IDARUBICIN; MITOXANTRONE; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DRUG COST; FEMALE; HEALTH CARE COST; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; PROPHYLAXIS; THRUSH; WARD;

COST-EFFECTIVENESS; COSTS; NEUTROPENIA; PHARMACOECONOMIC ANALYSIS; POSACONAZOLE; PROPHYLAXIS;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; CHEMOPREVENTION; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; FEMALE; HEALTH CARE COSTS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYCOSES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TRIAZOLES; YOUNG ADULT;

EID: 84892838105     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12105     Document Type: Article

References (38)

1. Lass-Florl C. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 2009; 52: 197-205.
2. Pagano L, Caira M, Candoni A et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91: 1068-75.
3. Greene RE, Schlamm HT, Oestmann JW et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007; 44: 373-9.
4. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
5. Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-59.
6. Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-47.
7. Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845-51.
8. Bohme A, Ruhnke M, Buchheidt D et al. Treatment of invasive fungal infections in cancer patients-recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2009; 88: 97-110.
9. Lyman GH. A comparison of international guidelines for the prevention of chemotherapy-induced neutropenia. Curr Opin Hematol 2010; [Epub ahead of print].
10. Freifeld AG, Bow EJ, Sepkowitz KA et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52: e56-93.
11. Vehreschild JJ, Ruping MJ, Wisplinghoff H et al. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. J Antimicrob Chemother 2010; 65: 1466-71.
12. Maertens JA, Nucci M, Donnelly JP. The role of antifungal treatment in hematology. Haematologica 2012; 97: 325-7.
13. Bohme A, Atta J, Mousset S et al. Antifungal management and resource use in patients with acute myeloid leukaemia after chemotherapy-retrospective analysis of changes over 3 yr in a German hospital. Eur J Haematol 2012; 88: 68-77.
14. Sozialgesetzbuch V. Öffentliches Gesundheitswesen § 139a Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen [WWW document], 2012. URL http://www.gesetze-im-internet.de/sgb_5/__139a.html [accessed on 21 June 2012]
15. Sozialgesetzbuch V.Öffentliches Gesundheitswesen § 35b Kosten-Nutzen-Bewertung von Arzneimitteln [WWW document], 2012. URL http://www.gesetze-im-internet.de/sgb_5/__35b.html [accessed on 21 June 2012].
16. Slobbe L, Polinder S, Doorduijn JK et al. Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study. Clin Infect Dis 2008; 47: 1507-12.
17. Rieger CT, Cornely OA, Hoppe-Tichy T et al. Treatment cost of invasive fungal disease (Ifd) in patients with acute myelogenous leukaemia (Aml) or myelodysplastic syndrome (Mds) in German hospitals. Mycoses 2012; 55: 514-20.
18. Michallet M, Gangneux JP, Lafuma A et al. Cost effectiveness of posaconazole in the prophylaxis of invasive fungal infections in acute leukaemia patients for the French healthcare system. J Med Econ 2011; 14: 28-35.
19. Jansen JP, O'Sullivan AK, Lugtenburg E, Span LF, Janssen JJ, Stam WB. Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands. Ann Hematol 2010; 89: 919-26.
20. Lyseng-Williamson KA. Posaconazole: a pharmacoeconomic review of its use in the prophylaxis of invasive fungal disease in immunocompromised hosts. Pharmacoeconomics 2011; 29: 251-68.
21. Al-Badriyeh D, Slavin M, Liew D et al. Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia. J Antimicrob Chemother 2010; 65: 1052-61.
22. O'Sullivan AK, Pandya A, Papadopoulos G et al. Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States. Value Health 2009; 12: 666-73.
23. Collins CD, Ellis JJ, Kaul DR. Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia. Am J Health Syst Pharm 2008; 65: 2237-43.
24. InEK-GmbH. The G-DRG Report-Browser [WWW document], 2011. URL http://www.g-drg.de/cms/Archiv#sj2005dj2003 [accessed on 1 August 2011].
25. Martin J, Neurohr C, Bauer M, Weiss M, Schleppers A. Cost of intensive care in a German hospital: cost-unit accounting based on the InEK matrix. Anaesthesist 2008; 57: 505-12.
26. GoÄ. Gebührenordnung für Ärzte [WWW document], 2011. URL http://www.e-bis.de/goae/defaultFrame.htm [accessed on 1 August 2011].
27. Hillner BE, Smith TJ. Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing. J Clin Oncol 2009; 27: 2111-3.
28. Edbrooke DL, Ridley SA, Hibbert CL, Corcoran M. Variations in expenditure between adult general intensive care units in the UK. Anaesthesia 2001; 56: 208-16.
29. Jacobs P, Rapoport J, Edbrooke D. Economies of scale in British intensive care units and combined intensive care/high dependency units. Intensive Care Med 2004; 30: 660-4.
30. Solberg BC, Dirksen CD, Nieman FH, van Merode G, Poeze M, Ramsay G. Changes in hospital costs after introducing an intermediate care unit: a comparative observational study. Crit Care 2008; 12: R68.
31. Gesundheitsberichterstattung des Bundes. Diagnosedaten der Krankenhäuser ab 2000 (Eckdaten der vollstationären Patienten und Patientinnen) [WWW document], 2013. URL http://www.gbe-bund.de/oowa921-install/servlet/oowa/aw92/dboowasys921.xwdevkit/xwd_init?gbe.isgbetol/xs_start_neu/&p_aid=3&p_aid=94220310&nummer=550&p_sprache=D&p_indsp=-&p_aid=43659367 [accessed on 24 February 2013].
32. Dranitsaris G, Khoury H. Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis. Support Care Cancer 2011; 19: 1807-13.
33. Greiner RA, Meier Y, Papadopoulos G, O'Sullivan AK, Imhof A. Cost-effectiveness of posaconazole compared with standard azole therapy for prevention of invasive fungal infections in patients at high risk in Switzerland. Oncology 2010; 78: 172-80.
34. Klaus B, Ritter A, Grosse Hulsewiesche H et al. Study of the quality of codification of diagnoses and procedures under DRG conditions. Gesundheitswesen 2005;67: 9-19.
35. Steinbusch PJ, Oostenbrink JB, Zuurbier JJ, Schaepkens FJ. The risk of upcoding in casemix systems: a comparative study. Health Policy 2007; 81: 289-99.
36. Hsia DC, Krushat WM, Fagan AB, Tebbutt JA, Kusserow RP. Accuracy of diagnostic coding for Medicare patients under the prospective-payment system. N Engl J Med 1988; 318: 352-5.
37. Tennvall GR, Persson U, Nilsson B. The economic costs of acute myeloid leukemia in Sweden. Int J Technol Assess Health Care 1994; 10: 683-94.
38. Redaelli A, Botteman MF, Stephens JM, Brandt S, Pashos CL. Economic burden of acute myeloid leukemia: a literature review. Cancer Treat Rev 2004; 30: 237-47.